Screener
GoodRx Holdings, Inc. GDRX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by GoodRx Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: GoodRx Holdings, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001809519-26-000152
| (in thousands, except for per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net income | $8,536 | $12,843 | $9,705 | $23,895 |
| Earnings per share: | ||||
| Basic | $0.03 | $0.04 | $0.03 | $0.06 |
| Diluted | $0.02 | $0.04 | $0.03 | $0.06 |
| Weighted average shares used in computing earnings per share: | ||||
| Basic | 339,277 | 356,623 | 339,839 | 367,847 |
| Diluted | 348,058 | 357,159 | 344,676 | 368,345 |
| Stock-based compensation included in costs and operating expenses: |
Item 1. Financial Statements
FAQ
- What is GoodRx Holdings, Inc.'s EPS (diluted)?
- GoodRx Holdings, Inc. (GDRX) reported EPS (diluted) of $0.02 in Q2 2026.
- How has GoodRx Holdings, Inc.'s EPS (diluted) changed year-over-year?
- GoodRx Holdings, Inc.'s EPS (diluted) decreased by 50.0% year-over-year, from $0.04 to $0.02.
- What is the long-term trend for GoodRx Holdings, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), GoodRx Holdings, Inc.'s EPS (diluted) has grown at a 10.7% compound annual growth rate (CAGR), from -$0.06 to $0.09.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about GoodRx Holdings, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude